ArticleMolecular medicine reports2018
Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Niclosamide is a potential candidate for the treatment of chemo-resistant osteosarcoma.Genetics and molecular biology · 2023Article
- Ferroptosis as a Potential Cell Death Mechanism Against Cisplatin-Resistant Lung Cancer Cell Line.Advanced pharmaceutical bulletin · 2023Article
- Niclosamide-A promising treatment for COVID-19.British journal of pharmacology · 2022Review
- Double Repositioning: Veterinary Antiparasitic to Human Anticancer.International journal of molecular sciences · 2022Review
- Release of nifedipine, furosemide, and niclosamide drugs from the biocompatible poly(HEMA) hydrogel structures.Turkish journal of chemistry · 2022Article
- The magic bullet: Niclosamide.Frontiers in oncology · 2022Review
- Article
- The Role of Non-Coding RNAs in the Regulation of the Proto-Oncogene MYC in Different Types of Cancer.Biomedicines · 2021Review
- Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.Journal of cancer research and clinical oncology · 2020Article
- Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.Oncology reports · 2020Article
- Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota.Nature communications · 2018Article
- Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells.Molecules (Basel, Switzerland) · 2018Article
- Niclosamide, a Drug with Many (Re)purposes.ChemMedChem · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a leading cause of cancer-associated mortality worldwide. The cisplatin (DDP)‑based chemotherapy remains the foundation of treatment for the majority of patients affected by advanced non‑small cell lung cancer (NSCLC). However, DDP‑resistance limits the clinical utility of this drug in patients with advanced NSCLC. The aim of the present study was to investigate the inhibitory effect of niclosamide on human lung cancer cell growth and to investigate the possible underlying mechanism. The effects of niclosamide on the proliferation of human lung adenocarcinoma (A549) and DDP‑resistant (CR) human lung adenocarcinoma (A549/DDP) cells were examined by Cell Counting kit‑8 assay. The impact of niclosamide on the apoptosis of A549/DDP cells was detected by Annexin V‑fluorescein isothiocyanate/propidium iodide assay. The expression levels of cisplatin‑resistant‑associated molecules (lung resistance‑related protein and c‑myc) following niclosamide treatment in A549/DDP cells were evaluated by western blot analysis. The results indicated that niclosamide in combination with DDP demonstrated a synergistic effect in A549/DDP cells and directly induced apoptosis, which may be associated with caspase‑3 activation. Furthermore, niclosamide decreased the expression level of c‑myc protein, which may influence DDP sensitivity of A549/DDP cells. Thus, the present study indicates that niclosamide combined with DDP exerts a synergistic effect in cisplatin‑resistant lung cancer cells and may present as a promising drug candidate in lung cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.